Leap Therapeutics, Inc. (LPTX)

Market Cap	83.72M
Revenue (ttm)	n/a
Net Income (ttm)	-81.41M
Shares Out	25.60M
EPS (ttm)	-3.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,025
Open	3.190
Previous Close	3.290
Day's Range	3.110 - 3.258
52-Week Range	1.235 - 10.200
Beta	0.59
Analysts	Strong Buy
Price Target	11.38 (+251.24%)
Earnings Date	May 13, 2024

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: LPTX

Analyst Forecast

According to 4 analysts, the average rating for LPTX stock is "Strong Buy." The 12-month stock price forecast is $11.38, which is an increase of 251.24% from the latest price.

Price Target

$11.38

(251.24% upside)

Analyst Consensus: Strong Buy